Clinical Trial Update: Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency [Phase 1]

View source ↗

Summary

This clinical trial update describes an ongoing Phase 1 study evaluating imatinib to increase RUNX1 activity in individuals with germline RUNX1 deficiency, curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Platelet Disorder with Predisposition to Myeloid Malignancies
• Inherited Bone Marrow Failure Syndrome

Drugs mentioned

• Imatinib (imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Inherited Bone Marrow Failure Syndrome, Familial Platelet Disorder With Predisposition to Myeloid Malignancies | Phase 1 | Status: RECRUITING